ArticleBehavioural neurology2026
GLP-1 Agonist Attenuates Nicotine Reward-Related Behavior by Regulating the Prepro-Orexin in the Hypothalamus and Prepro-Glucagon in the Nucleus Tractus Solitarius.
Article in Behavioural neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Tobacco consumption has significantly increased globally, contributing to various degenerative diseases such as lung cancer and cardiovascular disorders. Nicotine, the primary addictive component in tobacco, exerts its effects by stimulating nicotinic acetylcholine receptors (nAChRs), leading to excessive dopamine release in the ventral tegmental area (VTA) and nucleus accumbens (NAc), which underlies its rewarding and addictive properties. Additionally, nicotine enhances orexin activity in the hypothalamus and prepro-glucagon expression in the nucleus tractus solitarius (NTS), further reinforcing addictive behaviors. This study is aimed at investigating the effects of liraglutide, a GLP-1 receptor agonist, on nicotine-induced reward. Male mice strain ddy were divided into four groups: control, nicotine, nicotine + liraglutide (50 μg/kg), and nicotine + liraglutide (100 μg/kg). The conditioned place preference (CPP) test was used to evaluate nicotine's rewarding effects, whereas RT-PCR assessed the expression of prepro-orexin and prepro-glucagon mRNA in the hypothalamus and NTS, respectively. The results confirmed that nicotine administration (0.5 mg/kg) significantly increased CPP scores, indicating enhanced reward-related behaviors. Correspondingly, nicotine elevated prepro-orexin and prepro-glucagon mRNA expression levels. Treatment with liraglutide (50 and 100 μg/kg) significantly reduced nicotine-induced CPP scores, suggesting an attenuation of addictive behavior. Liraglutide downregulated the expression of prepro-orexin and prepro-glucagon, with the 100 μg/kg dose demonstrating greater efficacy in normalizing prepro-glucagon levels. These findings indicate that liraglutide mitigates nicotine reward by modulating neuropeptide pathways, including orexin and glucagon signaling. The dual impact of liraglutide on behavioral and molecular markers highlights its potential as a therapeutic agent for treating nicotine induce reward-related behavior. Further research is warranted to explore its long-term efficacy and underlying mechanisms in addiction modulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.